PT  - JOURNAL ARTICLE
AU  - Norland, Kristjan
AU  - Schaid, Daniel J.
AU  - Naderian, Mohammadreza
AU  - Na, Jie
AU  - Kullo, Iftikhar J.
TI  - Joint Association of Polygenic Risk and Social Determinants of Health with Coronary Heart Disease in the United States
AID  - 10.1101/2024.01.10.24301105
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.10.24301105
4099  - http://medrxiv.org/content/early/2024/01/11/2024.01.10.24301105.short
4100  - http://medrxiv.org/content/early/2024/01/11/2024.01.10.24301105.full
AB  - Background The joint effects of polygenic risk and social determinants of health (SDOH) on coronary heart disease (CHD) in the United States are unknown.Methods In 67,256 All of Us (AoU) participants with available SDOH data, we ascertained self-reported race/ethnicity and calculated a polygenic risk score for CHD (PRSCHD). We used 90 SDOH survey questions to develop an SDOH score for CHD (SDOHCHD). We assessed the distribution of SDOHCHD across self-reported races and US states. We tested the joint association of SDOHCHD and PRSCHD with CHD in regression models that included clinical risk factors.Results SDOHCHD was highest in self-reported black and Hispanic people. Self-reporting as black was associated with higher odds of CHD but not after adjustment for SDOHCHD. Median SDOHCHD values varied by US state and were associated with heart disease mortality. A 1-SD increase in SDOHCHD was associated with CHD (OR=1.36; 95% CI, 1.29 to 1.46) and incident CHD (HR=1.73; 95% CI, 1.27 to 2.35) in models that included PRSCHD and clinical risk factors. Among people in the top 20% of PRSCHD, CHD prevalence was 4.8% and 7.8% in the bottom and top 20% of SDOHCHD, respectively.Conclusions Increased odds of CHD in self-reported black people are likely due to higher SDOH burden. SDOH and PRS were independently associated with CHD in the US. Our findings emphasize the need to consider both PRS and SDOH for equitable disease risk assessment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium through the National Human Genome Research Institute (NHGRI): grant U01 HG11710, the electronic Medical Records and Genomics (eMERGE) Network funded by the NHGRI: grant U01 HG06379, and a National Heart, Lung, and Blood: grant K24 HL137010, and GM065450.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mayo Clinic gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes